did the fda ban tirzepatide Grants a New Indication for Obesity Management FDA says shortage of GLP-1

Understanding the science behind semaglutide medications can help you understand whether semaglutide is the right option for you

In: Antioxidants effects in health: the bright and the dark side

Tirzepatide (Mounjaro) activates two pathways simultaneouslyGLP-1 and GIP receptorscreating what researchers call a 'dual-hormone' effect

Xiao N, Devarajan P, Inge TH, Jenkins TM, Bennett M, Mitsnefes MM

Key Economic Modeling Outcomes Guided by the commonly used threshold of $50,000 per QALY in Canada, the most important findings are as follows: At a 60% reduction from the 2025 pre-generic semaglutide price paid by the Quebec provincial drug plan, combined GLP-1RA and SGLT2i therapy may become the preferred strategy for this guideline-indicated cohort of patients, compared to either therapy alone or other standard-of-care therapies